Skip to content

Role of Arterial Spin Labelling Magnetic Resonance Prefusion in Grading of Pediatric Brain Tumors

Role of Arterial Spin Labelling Magnetic Resonance Perfusion in The Grading of Pediatric Brain Tumors

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07427316
Enrollment
20
Registered
2026-02-23
Start date
2026-03-01
Completion date
2028-04-01
Last updated
2026-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Brain Tumors

Keywords

ASL MRI, arterial spin labelling, magnetic resonance perfusion

Brief summary

To evaluate the diagnostic performance of arterial spin labelling (ASL) magnetic resonance perfusion in preoperative grading of pediatric brain tumors.

Detailed description

Pediatric brain tumors are one of the most common malignancies in children and represent a leading cause of cancer-related morbidity and mortality worldwide. Accurate preoperative tumor grading plays a pivotal role in determining treatment strategies, surgical planning, prognosis and long-term follow-up. Histopathological grading remains the reference standard; however, non-invasive imaging capable of predicting tumor grade preoperatively are increasingly sought to optimize patient management. Conventional magnetic resonance imaging (MRI) provides excellent anatomical resolution and lesion localization; nevertheless, substantial overlap persists in morphological imaging features between low-grade and high-grade pediatric brain tumors. In children, contrast enhancement does not correlate with tumor grade, unlike the way it does in adults. Diffusion parameters overlap between benign and aggressive lesions as well, limiting the accuracy of conventional MRI in reliable tumor grading when used alone. Advanced MRI techniques, particularly perfusion imaging, have emerged as valuable adjuncts for tumor characterization by evaluating tumor vascularity and microcirculation. Arterial spin labelling (ASL) is a non-contrast perfusion MRI technique that quantifies cerebral blood flow (CBF) using magnetically labeled arterial blood water as an endogenous tracer. This technique is especially advantageous in the pediatric population, as it eliminates exposure to gadolinium-based contrast agents and avoids ionizing radiation, aligning with current safety recommendations in children. High-grade pediatric brain tumors typically demonstrate increased angiogenesis, microvascular proliferation and elevated perfusion compared with low-grade tumors. Recent studies have shown that ASL-derived perfusion parameters correlate with tumor grade and histopathological aggressiveness in pediatric brain tumors. Despite growing evidence supporting its diagnostic value, arterial spin labelling (ASL) remains underutilized in routine clinical practice for pediatric brain tumor grading. Further prospective studies are required to validate its diagnostic performance and establish its role as a reliable non-invasive imaging biomarker.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

1. Pediatric patients aged 18 years or younger. 2. Patients with radiological diagnosis of intracranial brain tumors.

Exclusion criteria

1. Patients who have received prior surgery, chemotherapy or radiotherapy for brain tumors. 2. Patients with contraindications to magnetic resonance imaging (MRI) examination.

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the diagnostic value of arterial spin labelling (ASL) magnetic resonance perfusion in pre-operative grading of pediatric brain tumorspreoperativearterial spin labelling (ASL) derived cerebral blood flow values and their correlation with histopathological tumor grade (low grade versus high grade pediatric brain tumor)

Contacts

CONTACTMonica Boles
monica.sobhy94@gmail.com+20 01278489110
STUDY_CHAIRMostafa Elsharkawy, Professor

Assiut university hospitals

STUDY_DIRECTORRadwa Kamel, associate professor

Assiut university hospitals

STUDY_DIRECTORHamdy Ibrahim

Assiut university hospitals

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026